Abbott Laboratories $ABT Shares Bought by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 481,458 shares of the healthcare product maker’s stock after buying an additional 24,559 shares during the quarter. Harvest Portfolios Group Inc.’s holdings in Abbott Laboratories were worth $60,322,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $27,000. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the third quarter worth $31,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter worth $33,000. Finally, Copia Wealth Management purchased a new position in shares of Abbott Laboratories in the third quarter worth $38,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the subject of a number of research reports. The Goldman Sachs Group decreased their target price on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Barclays decreased their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Stifel Nicolaus decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Wells Fargo & Company lowered their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Argus lowered their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $88.81 on Wednesday. The stock has a market capitalization of $154.70 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 1.47 and a beta of 0.65. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The firm’s 50 day simple moving average is $98.14 and its 200-day simple moving average is $112.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter last year, the company earned $1.09 EPS. The business’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.